|
Apr 8
|
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
|
|
Apr 5
|
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
|
|
Apr 5
|
Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive?
|
|
Apr 5
|
Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)
|
|
Apr 1
|
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
|
|
Mar 21
|
11 Best Healthcare ETFs To Buy Now
|
|
Mar 20
|
Will Natera (NTRA) Continue to Deliver Solid Topline Growth?
|
|
Mar 18
|
Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain
|
|
Mar 18
|
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
|
|
Mar 14
|
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
|
|
Mar 12
|
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
|
|
Mar 8
|
SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA)
|
|
Mar 7
|
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
|
|
Mar 4
|
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
|
|
Mar 2
|
Natera Full Year 2023 Earnings: Beats Expectations
|
|
Mar 1
|
Decoding Natera Inc (NTRA): A Strategic SWOT Insight
|
|
Feb 29
|
Q4 2023 Natera Inc Earnings Call
|
|
Feb 29
|
Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript
|
|
Feb 29
|
Natera to Participate in March Investor Conferences
|
|
Feb 28
|
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
|